{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:11:06Z","timestamp":1787987466061,"version":"build-2784847793"},"reference-count":19,"publisher":"Japan Society for Clinical Immunology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2177\/jsci.38.65","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T22:07:53Z","timestamp":1425938873000},"page":"65-68","source":"Crossref","is-referenced-by-count":2,"title":["Abnormal expression of chemokine receptor on B cells in patients with SLE"],"prefix":"10.2177","volume":"38","author":[{"given":"Maiko","family":"YOSHIKAWA","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"NAKAYAMADA","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"IWATA","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"KUBO","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"YUNOUE","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheau-Pey","family":"WANG","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"TANAKA","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"972","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tanaka, Y.: Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. <i>Inter Med<\/i>. <b>46<\/b>: 1313-1315, 2007.","DOI":"10.2169\/internalmedicine.46.1914"},{"key":"2","unstructured":"2) Sandra, V.N., et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Lancet<\/i>. <b>377<\/b>: 721-731, 2011."},{"key":"3","unstructured":"3) Tanaka, Y., et al.: A multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus. <i>Mod Rheumatol<\/i>. <b>17<\/b>: 191-197, 2007."},{"key":"4","unstructured":"4) Anolik, J.H., et al.: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. <i>Arthritis Rheum<\/i>. <b>50<\/b>: 3580-3590, 2004."},{"key":"5","unstructured":"5) Cambridge, G., et al.: B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. <i>Arthritis Rheum<\/i>. <b>54<\/b>: 3612-3622, 2006."},{"key":"6","unstructured":"6) Rovin, B.H., et al.: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. <i>Arthritis Rheum<\/i>. <b>64<\/b>: 1215-1226, 2012."},{"key":"7","unstructured":"7) Merrill, J.T., et al.: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis Rheum<\/i>. <b>62<\/b>: 222-233, 2010."},{"key":"8","unstructured":"8) Iwata, S., et al.: B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. <i>Ann Rheum Dis<\/i>. <b>71<\/b>: 1749-1750, 2012."},{"key":"9","unstructured":"9) Jacobi, A.M., et al.: Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. <i>Arthritis Rheum<\/i>. <b>58<\/b>: 1762-1773, 2008."},{"key":"10","unstructured":"10) Jacobi, A.M., et al.: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. <i>Arthritis Rheum<\/i>. <b>48<\/b>: 1332-1342, 2003."},{"key":"11","unstructured":"11) Jenks, S.A., et al.: 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. <i>Arthritis Rheum<\/i>. <b>65<\/b>: 3165-3175, 2013."},{"key":"12","unstructured":"12) I\u00f1aki, S., et al.: B cells as therapeutic targets in SLE. <i>Nat Rev Rheumatol<\/i>. <b>6<\/b>: 326-337, 2010."},{"key":"13","unstructured":"13) Amy, M.B., et al.: SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. <i>PLoS One<\/i>. <b>8<\/b>: e67003, 2013."},{"key":"14","unstructured":"14) Bluestone, J.A., et al.: The functional plasticity of T cell subsets. <i>Nat Rev Immunol<\/i>. <b>9<\/b>: 811-816, 2009."},{"key":"15","unstructured":"15) Nakayamada, S., et al.: Helper T cell diversity and plasticity. <i>Curr Opin Immunol<\/i>. <b>24<\/b>: 297-302, 2012."},{"key":"16","unstructured":"16) Cannons, J.L., et al.: T follicular helper cell diversity and plasticity. <i>Trends Immunol<\/i>. <b>34<\/b>: 200-207, 2013."},{"key":"17","unstructured":"17) Lacotte, S., et al.: Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. <i>PLoS One<\/i>. <b>8<\/b>: e58140, 2013."},{"key":"18","unstructured":"18) Nicholas, M.W., et al.: A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. <i>Clin Immunol<\/i>. <b>126<\/b>: 189-201, 2008."},{"key":"19","unstructured":"19) Henneken, M., et al.: Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Res Ther<\/i>. <b>7<\/b>: R1001-1013, 2005."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u5168\u8eab\u6027\u30a8\u30ea\u30c6\u30de\u30c8\u30fc\u30c7\u30b9\uff08SLE\uff09\u60a3\u8005B\u7d30\u80de\u306b\u304a\u3051\u308b\u30b1\u30e2\u30ab\u30a4\u30f3\u53d7\u5bb9\u4f53\u767a\u73fe\u7570\u5e38"],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T06:58:55Z","timestamp":1498201135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/38\/1\/38_65\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.38.65","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}